bioMérieux Extends Food Testing Capabilities
with New AOAC RI Approval

Food matrix extension adds additional food groups
for VIDAS^® Listeria Species Xpress assay

Durham, N.C. (February 27, 2008) — bioMérieux, a leading industrial microbiology and diagnostics company, recently increased its food testing capabilities through a new AOAC Research Institute approval. bioMérieux received Performance Testing Method (PTM) approval for the food matrix extension for the VIDAS^® Listeria Species Xpress (LSX) test with Ottaviani Agosti Agar (OAA).

"The data from this evaluation demonstrated equivalent or better performance of the VIDAS LSX test with OAA Agar to the U.S. FDA and USDA reference methods," said Dr. Sharon Brunelle, technical consultant, AOAC Research Institute. "The VIDAS LSX test now covers a broader food matrix claim."

Originally, the VIDAS LSX test covered a select group of meats, dairy products and environmental surfaces. The recent AOAC approval expands this group by adding green beans, cauliflower, pasteurized crabmeat, frozen cod fillets, raw unpeeled shrimp, chicken franks and raw ground chicken.

“bioMérieux is excited to receive this additional approval for the VIDAS LSX test from the AOAC Research Institute,” said Herb Steward, Executive Vice President, bioMérieux, Inc. “This new extension allows us to offer a true Next Day™ solution, providing better service with enhanced testing capabilities to our target customers.”

The VIDAS LSX Solution combines the use of an innovative media (Listeria Xpress broth) for optimized Listeria enrichment and the VIDAS LSX assay. The LX broth reduces lag time and boosts organism recovery. The LSX assay utilizes a combination of polyclonal and monoclonal antibodies, which increases sensitivity and specificity. Results for environmental surfaces are available in about 26-28 hours, while meat and dairy results are available in about 30-34 hours after sampling.

About bioMérieux

Advancing Diagnostics to Improve Public Health

A world leader in the field of in vitro diagnostics for 45 years, bioMérieux is present in more than 150 countries through 37 subsidiaries and a large network of distributors. In 2007, revenues reached €1.063 billion with 84% of sales outside of France.

bioMérieux provides diagnostic solutions (reagents, instruments, software), which determine the source of disease and contamination to improve patient health and ensure consumer safety. Our products are used for diagnosing infectious diseases and providing high medical value results for cardiovascular emergencies and cancer screening and monitoring. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux.

Return to bioMérieux News